News

CE marking of ELISA assay with utility in Multiple Myeloma


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

CE marking of ELISA assay with utility in Multiple Myeloma

10/10/2016

Abingdon Health announces CE marking of Seralite®-FLC ELISA

Abingdon Health announce the CE marking of Seralite®-FLC ELISA, the latest addition to the Seralite® range. The introduction of an ELISA assay to measure serum free kappa and free lambda light chains means Abingdon Health now has the opportunity to offer its customers a simple, high-throughput method for detecting and measuring serum FLC levels.

The arrival of the Seralite®-FLC ELISA alongside Seralite®-FLC lateral flow immunoassay means that Abingdon Health’s customers now have available to them a range of tools, regardless of their workload. For Abingdon Health this addition to its portfolio cements its position as an innovator in the field of Multiple Myeloma and B-Cell Dyscrasia testing and demonstrates its continuing commitment to deliver unique solutions in this arena.

To read the full press release please visit www.abingdonhealth.com.

Visit us at Medica 2016

Abingdon Health will be visiting Medica 2016 where we will be seeking new commercial partners for Seralite®-FLC ELISA. For organisations interested in promoting Seralite®– FLC ELISA and becoming a commercial partner we would welcome the opportunity to meet with you at Medica.

To arrange a meeting with us at Medica please email Andrew Burns directly at info@abingdonhealth.com or complete the form on this link https://www.abingdonhealth.com/events/medica-trade-fair-2016/.


CompanyAbingdon Health
Company Websitehttps://www.abingdonhealth.com
Contact NameAndrew Burns
Contact Emailinfo@abingdonhealth.com

© Catalyst Innovation Portal 2019